Abstract:The beta-catenin pathway plays a critical role in the pathogenesis of certain types of cancers. To gain insight into mechanisms by which altered receptor tyrosine kinases regulate cytoplasmic beta-catenin accumulation, the effect of an oncogenic receptor originated from Nantes (RON) variant on beta-catenin accumulation and the role of beta-catenin in RON-mediated tumorigenic activities were studied. In NIH3T3 cells harboring oncogenic variant RON Delta 160, increased beta-catenin accumulation with tyrosine phosphorylation and nuclear translocation was observed. Overexpression of RON Delta 160 also resulted in increased expression of beta-catenin target genes c-myc and cyclin D1. By analyzing cellular proteins that regulate beta-catenin stabilities, it was found that RON Delta 160 activates the protein disheveled (DVL) and inactivates glycogen synthase kinase-3 beta by Ser-9 residue phosphorylation. These effects were channeled by RON Delta 160-activated PI 3-kinase-AKT pathways that are sensitive to specific inhibitors, such as wortmannin, but not to other chemical inhibitors. Silencing RON Delta 160 expression by specific small interfering RNA blocked not only beta-catenin expression but also c-myc and cyclin D1 expression, suggesting that RON expression is required for the activation of the beta-catenin signaling pathway. Moreover, it was found that knockdown of the beta-catenin gene expression by small interfering RNA techniques reduces significantly the RON Delta 160-mediated NIH3T3 cell proliferation, focus-forming activities and anchorage-independent growth. Thus, the oncogenic RON variant regulates beta-catenin stabilities through activation of DVL and inactivation of glycogen synthase kinase-3 beta. The activated beta-catenin cascade is one of the pathways involved in tumorigenic activities mediated by the oncogenic RON variant.

Point Mutation at Single Tyrosine Residue of Novel Oncogene Nok Abrogates Tumorigenesis in Nude Mice

A Novel Protein Tyrosine Kinase Nok That Shares Homology With Platelet-Derived Growth Factor/Fibroblast Growth Factor Receptors Induces Tumorigenesis And Metastasis In Nude Mice

The Carboxyl Terminal Tyrosine 417 Residue of Nok Has an Autoinhibitory Effect on Nok-Mediated Signaling Transductions

Transmembrane Helix of Novel Oncogene with Kinase-Domain (NOK) Influences Its Oligomerization and Limits the Activation of RAS/MAPK Signaling

Mechanisms of Cytoplasmic β-Catenin Accumulation and Its Involvement in Tumorigenic Activities Mediated by Oncogenic Splicing Variant of the Receptor Originated from Nantes Tyrosine Kinase

Nok Interacts With Akt And Enhances Its Activation

The potent oncogene NPM-ALK mediates malignant transformation of normal human CD4(+) T lymphocytes

NOK promotes tumorigenesis through coordinating epidermal growth factor receptor to boost the downstream signaling in breast cancer

High Novel Oncogene with Kinase-Domain (NOK) Gene Expression is Associated with the Progression of Renal Cell Carcinoma.

Generation and application of the NOK/STYK1 monoclonal antibody

NOK/STYK1 Interacts with GSK-3β and Mediates Ser9 Phosphorylation Through Activated Akt

Molecular and Functional Characterizations of the Association and Interactions Between Nucleophosmin-Anaplastic Lymphoma Kinase and Type I Insulin-Like Growth Factor Receptor

Nok Activates Stat3 Signaling by A Jak2-Dependent Mechanism

Phosphorylation of TOPK at Y74, Y272 by Src increases the stability of TOPK and promotes tumorigenesis of colon

NOK/STYK1 Has a Strong Tendency Towards Forming Aggregates and Colocalises with Epidermal Growth Factor Receptor in Endosomes

NOK Associates with C-Src and Promotes C-Src-induced STAT3 Activation and Cell Proliferation.

[Effect of Tyrosine Phosphorylation Sites of Oncogenic Protein NPM-ALK on Cell Cycle and Its Related Mechanisms].

Clinicopathologic features and prognostic implications of NOK/STYK1 protein expression in non-small cell lung cancer

Figure S5 from Oncogenic Kinase–Induced PKM2 Tyrosine 105 Phosphorylation Converts Nononcogenic PKM2 to a Tumor Promoter and Induces Cancer Stem–like Cells

NTRK1 is a positive regulator of YAP oncogenic function

NOK/STYK1 Promotes the Genesis and Remodeling of Blood and Lymphatic Vessels During Tumor Progression